Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Phase 1

Completed

• Conditions: Mild Cognitive Impairment
• Interventions: Biological: Plasma infusion; Biological: Plasmapheresis

• Registration Number: NCT03887741
• Lead Sponsor: Mayo Clinic

Brief Summary

Determine safety of plasma infusion or exchange in APOE 44 patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-03-21
• Study First Submitted QC: 2019-03-21
• Study First Posted: 2019-03-25
• Study Start: 2021-09-15
• Primary Completion: 2024-02-16
• Study Completion: 2024-02-16
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-30
• Last Update Posted: 2024-12-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Plasma infusion	Plasma infusion	3 patients will have biweekly plasma infusion for 6 months and followed for 12 months
Plasmapheresis	Plasmapheresis	3 patients will have monthly plasmapheresis for 6 months and followed for a total of 12 months

Primary Outcome Measures

Name	Time	Method
Adverse events	One year	Number of adverse events reported

Trial Locations

Locations (1)

Mayo Clinic in Florida; 🇺🇸 Jacksonville, Florida, United States